Mangoceuticals a secure telemedicine platform under the brands MangoRx and PeachesRx, has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and Wegovy® (semaglutide) from Novo Nordisk.
These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly’s LillyDirect® Self Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy. Through MangoRx and PeachesRx’s secure telehealth platform, customers will receive virtual consultations with board-certified providers, personalized obesity and weight management treatment plans, ongoing clinical monitoring and support, and to the extent eligible, fulfillment of these U.S. Food and Drug Administration (FDA)-approved GLP-1 medications via partner pharmacies or through their neighborhood pharmacies of choice.
“We’re working to make world-class weight-loss treatment simple and sustainable,” said Jacob Cohen, CEO of Mangoceuticals. “For just $99/month, our medication management membership, includes unlimited telehealth visits, personalized progress tracking, and lifestyle coaching. GLP-1 medications are provided separately at fixed cash-pay pricing through LillyDirect® and NovoCare programs, starting as low as $499 per month with free home delivery. Patients also have the flexibility to pick up prescriptions at their neighborhood pharmacies of choice upon request. No insurance is required, making the programs ideal for self-pay, uninsured, underinsured and high-deductible patients.”
This launch supports and comes in conjunction with the White House’s recent historic announcement, securing landmark deals with Eli Lilly and Novo Nordisk to reduce government pricing of certain GLP-1 medications to $245/month, offer $50 copays for Medicare patients with obesity (effective mid-2026), launch oral GLP-1 starters as low as $149/month via TrumpRx (to the extent approved by the FDA), and work to drive average costs for Wegovy and Zepbound to $350 or less per month.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!